The .gov means it’s official. Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you're on a federal government site.
The site is secure. The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.
On Oct. 1, 2024, the FDA began implementing a reorganization impacting many parts of the agency. We are in the process of updating FDA.gov content to reflect these changes.
Under the FDA reorganization, implemented October 1, 2024, the Office of the Chief Scientist (OCS) has expanded its purview through the creation of new sub-components and realignment of pre-existing components. These changes to OCS will enhance the Office’s ability to support the research foundation, science, and innovation that underpins FDA’s regulatory mission. All components impacted by the reorganization are shown below in blue within the organization chart and are highlighted below:
To download a copy of this organization chart and the functions summaries of OCS and each sub-component, please click here.
OOSH was created by merging the Office of Laboratory Safety and the Office of Operation’s (OO’s) Employee Safety and Occupational Health (ESOH) within the Office of Facilities Engineering and Mission Support Services (OFEMS).
OSLES was created by transferring functions from ORA’s Office of Medical Products Laboratory Operations within the Office of Regulatory Science to directly report to OCS.
OARL was created by moving resources from the ORA’ Office of Regulatory Science, Office of Medical Products Laboratory Operations, including substructure organizations and functions, to directly report to OCS.